A novel 5-HT3 receptor agonist, YM-31636, increases gastrointestinal motility without increasing abdominal pain

Abstract We examined the effects of YM-31636 (2-(1 H -imidazol-4-ylmethyl)-8 H -indeno[1,2- d ]thiazole monofumarate), a novel 5-HT 3 receptor agonist, on gastrointestinal functions including visceral pain reflex in rats. Injection of YM-31636 increased the number of fecal pellets. This effect was completely inhibited by ramosetron, a 5-HT 3 receptor antagonist. YM-31636 also increased the intracolonic pressure measured in both conscious and anesthetized rats. In isolated distal colon, YM-31636 increased the short-circuit current response. This effect was abolished by ramosetron. Both the maximal response and the potency of YM-31636 were weaker than those of other 5-HT 3 receptor agonists. In two visceral pain reflex models, YM-31636 neither changed the magnitude of pressor response to colonic distension in anesthetized rats nor affected the visceromotor threshold to colorectal distension in conscious rats. In conclusion, YM-31636 facilitated defecation without increasing visceral pain. Consequently, 5-HT 3 receptor agonists like YM-31636 would be promising in the treatment of chronic constipation.